This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Dinu, A R Articles by Lahita, R G Search for Related Content PubMed PubMed Citation Articles by Dinu, A R Articles by Lahita, R G Social Bookmarking                         What's this?

Fequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE

J T Merrill

C Shen

Division of Rheumatology, Department of Medicine, St Lukes-Roosevelt Hospital Center, New York, NY

I V Antonov

B L Myones

Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA

R G Lahita

Division of Rheumatology, Department of Medicine, St Lukes-Roosevelt Hospital Center, New York, NY

In examining reasons for premature atherosclerosis in systemic lupus erythematosus (SLE), we previously reported low levels of the cholesterol transport protein apolipoprotein A1 (apoA1) in these patients, and specific antibodies to purified apoA1 were identified in the sera of 5 out of 30 lupus patients. The current study was initiated to determine whether these antibodies are common in lupus patients. 520 serum samples from 175 patients with SLE or primary antiphospholipid syndrome (PAPS) were tested for antibodies to purified apoA1. Positive sera were retested for binding to apolipoprotein incorporated into reconstructed nascent or mature high-density lipoprotein (HDL). Autoantibodies to apoA1 were found in 32.5% of patients with SLE and 22.9% of patients with PAPS, associated with the presence of aPL (anti-ß₂ glycoprotein-1, antiß₂ GP1) antibodies. When reconstructed, nascent and mature HDL molecules were compared as antigen-containing environments, positive sera reacted best to apoA1 embedded in mature HDL molecules. This report confirms the high prevalence of antibodies to apoA1 in patients with systemic lupus and suggests a high affinity of these antibodies for mature HDL.

Key Words: apolipoprotein A1 • HDL • autoantibodies • systemic lupus erythematosus

Lupus, Vol. 7, No. 5, 355-360 (1998)
DOI: 10.1191/096120398678920262


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Charakida, C. Besler, J. R. Batuca, S. Sangle, S. Marques, M. Sousa, G. Wang, D. Tousoulis, J. Delgado Alves, S. P. Loukogeorgakis, et al. Vascular Abnormalities, Paraoxonase Activity, and Dysfunctional HDL in Primary Antiphospholipid Syndrome JAMA, September 16, 2009; 302(11): 1210 - 1217. [Abstract] [Full Text] [PDF]

				J. R. Batuca, P. R. J. Ames, M. Amaral, C. Favas, D. A. Isenberg, and J. Delgado Alves Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus Rheumatology, January 1, 2009; 48(1): 26 - 31. [Abstract] [Full Text] [PDF]

				M McMahon, J Grossman, W Chen, and B H Hahn Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 59 - 69. [Abstract] [PDF]

				S I van Leuven, J J. Kastelein, D P D'Cruz, G R Hughes, and E S Stroes Atherogenesis in rheumatology Lupus, March 1, 2006; 15(3): 117 - 121. [Abstract] [PDF]

				I. N. Bruce 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus Rheumatology, December 1, 2005; 44(12): 1492 - 1502. [Abstract] [Full Text] [PDF]

				I N Bruce Atherogenesis and autoimmune disease: the model of lupus Lupus, September 1, 2005; 14(9): 687 - 690. [Abstract] [PDF]

				J-M. Dayer How T-lymphocytes are activated and become activators by cell{-}cell interaction Eur. Respir. J., September 20, 2003; 22(44_suppl): 10s - 15s. [Full Text] [PDF]

				J. Delgado Alves, S. Kumar, and D. A. Isenberg Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome Rheumatology, July 1, 2003; 42(7): 893 - 899. [Abstract] [Full Text] [PDF]

				A. J. Mendez, R. B. Goldberg, P. I. Arnold, and D. R. Schultz Acquired HDL Deficiency Associated With Apolipoprotein A-I Reactive Monoclonal Immunoglobulins Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1740 - 1741. [Full Text] [PDF]

				G NAGY, A HORVATH, G FUST, L ROMICS, I KARADI, P GERGELY, G NAGY, P GERGELY, G NAGY, A HORVATH, et al. Anticholesterol antibody levels in patients with systemic lupus erythematosus Ann Rheum Dis, July 1, 2001; 60(7): 722 - 723. [Full Text] [PDF]

				N. Hyka, J.-M. Dayer, C. Modoux, T. Kohno, C. K. Edwards III, P. Roux-Lombard, and D. Burger Apolipoprotein A-I inhibits the production of interleukin-1{beta} and tumor necrosis factor-{alpha} by blocking contact-mediated activation of monocytes by T lymphocytes Blood, April 15, 2001; 97(8): 2381 - 2389. [Abstract] [Full Text] [PDF]

				S. Horkko, T. Olee, L. Mo, D. W. Branch, V. L. Woods Jr, W. Palinski, P. P. Chen, and J. L. Witztum Anticardiolipin Antibodies From Patients With the Antiphospholipid Antibody Syndrome Recognize Epitopes in Both {beta}2-Glycoprotein 1 and Oxidized Low-Density Lipoprotein Circulation, February 20, 2001; 103(7): 941 - 946. [Abstract] [Full Text] [PDF]

				S. Manzi Systemic lupus erythematosus: a model for atherogenesis? Rheumatology, April 1, 2000; 39(4): 353 - 359. [Full Text] [PDF]